Reported Earnings • May 18
First quarter 2026 earnings released: US$0.084 loss per share (vs US$0.20 loss in 1Q 2025) First quarter 2026 results: US$0.084 loss per share (improved from US$0.20 loss in 1Q 2025). Net loss: US$3.59m (loss narrowed 58% from 1Q 2025). Revenue is forecast to grow 65% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Announcement • Mar 12
VYNE Therapeutics Inc. Receives an Additional 180 Calendar Days Extension to Regain Compliance with the Minimum Bid Price Requirement As previously disclosed in a Current Report on Form 8-K filed by VYNE Therapeutics Inc. (the Company) on September 12, 2025, the Company received a notification from The Nasdaq Stock Market, LLC (Nasdaq) that the Company is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's common stock (the Common Stock) was below $1.00 per share for 30 consecutive business days. The Company initially had 180 calendar days, or until March 10, 2026, to regain compliance with the minimum bid price requirement. The Company was unable to regain compliance with the minimum bid price requirement by March 10, 2026. On March 11, 2026, the Company received a letter (the Extension Notice) from Nasdaq notifying the Company that its request for an extension to regain compliance with the minimum bid price requirement has been granted, and the Company has an additional 180 calendar days, or until September 7, 2026, to regain compliance with the minimum bid price requirement. Nasdaq's determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Extension Notice has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Capital Market and, at this time, the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol VYNE. If at any time before September 7, 2026, the bid price of the Company's common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will notify the Company that it is in compliance with the minimum bid price requirement. However, if compliance with the minimum bid price requirement cannot be demonstrated by September 7, 2026, Nasdaq will notify the Company that its common stock will be delisted from The Nasdaq Capital Market, at which time, the Company may appeal Nasdaq's determination to a Hearings Panel. The Company intends to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities during the second compliance period, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. Reported Earnings • Mar 02
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: US$0.63 loss per share (improved from US$0.94 loss in FY 2024). Net loss: US$26.7m (loss narrowed 33% from FY 2024). Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) exceeded analyst estimates by 26%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings. 
